Hartline Investment Corp’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Hartline Investment Corp’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.76M	Buy	13,797 +360	+3%	+$44.9K	0.19%	58
2025 Q4	$1.64M	Buy	+13,437	New	+$1.54M	0.18%	58
2025 Q1	–	Sell	-5,502	Closed	-$496K	–	104
2024 Q4	$496K	Hold	5,502	–	–	0.06%	78
2024 Q3	$544K	Buy	5,502 +106	+2%	+$10.4K	0.07%	78
2024 Q2	$500K	Buy	+5,396	New	+$484K	0.07%	80
2024 Q1	–	Sell	-5,396	Closed	-$482K	–	453
2023 Q4	$482K	Sell	5,396 -702	-12%	-$52.1K	0.08%	75
2023 Q3	$445K	Sell	6,098 -185	-3%	-$14.8K	0.08%	78
2023 Q2	$523K	Hold	6,283	–	–	0.09%	77
2023 Q1	$479K	Buy	6,283 +925	+17%	+$76.8K	0.1%	79
2022 Q4	$445K	Buy	+5,358	New	+$434K	0.1%	78
2022 Q3	–	Sell	-15,915	Closed	-$2.24M	–	218
2022 Q2	$2.24M	Buy	15,915 +1,276	+9%	+$95.8K	0.32%	48
2022 Q1	$1.98M	Buy	14,639 +9,185	+168%	+$848K	0.25%	59
2021 Q4	$611K	Sell	5,454 -7,009	-56%	-$845K	0.08%	79
2021 Q3	$1.57M	Sell	12,463 -2,176	-15%	-$280K	0.22%	62
2021 Q2	$1.98M	Sell	14,639 -1,379	-9%	-$181K	0.25%	59
2021 Q1	$2.17M	Buy	16,018 +103	+0.6%	+$15.4K	0.33%	51
2020 Q4	$2.24M	Sell	15,915 -2,342	-13%	-$300K	0.32%	48
2020 Q3	$2.03M	Sell	18,257 -8,643	-32%	-$969K	0.34%	46
2020 Q2	$3.01M	Sell	26,900 -23,026	-46%	-$2.27M	0.63%	33
2020 Q1	$3.87M	Sell	49,926 -1,244	-2%	-$110K	0.96%	25
2019 Q4	$4.87M	Buy	51,170 +370	+0.7%	+$32K	1.04%	25
2019 Q3	$3.87M	Buy	50,800 +765	+2%	+$63.6K	0.93%	24
2019 Q2	$4.39M	Buy	50,035 +2,703	+6%	+$231K	1.05%	25
2019 Q1	$4.29M	Buy	47,332 +13,897	+42%	+$1.18M	1.12%	23
2018 Q4	$2.4M	Sell	33,435 -4,792	-13%	-$386K	0.73%	27
2018 Q3	$3.67M	Buy	38,227 +7,901	+26%	+$766K	0.86%	25
2018 Q2	$2.89M	Buy	30,326 +165	+0.5%	+$15.2K	0.78%	32
2018 Q1	$2.65M	Sell	30,161 -1,045	-3%	-$95.4K	0.73%	32
2017 Q4	$2.65M	Sell	31,206 -61,076	-66%	-$5.12M	0.73%	40
2017 Q3	$7.99M	Buy	92,282 +1,070	+1%	+$85.8K	2.42%	7
2017 Q2	$7.04M	Sell	91,212 -50	-0.1%	-$3.55K	2.25%	9
2017 Q1	$6.33M	Buy	91,262 +18,948	+26%	+$1.27M	2.04%	10
2016 Q4	$4.28M	Buy	72,314 +10,775	+18%	+$665K	1.49%	13
2016 Q3	$4.08M	Sell	61,539 -1,375	-2%	-$85.1K	1.47%	15
2016 Q2	$3.4M	Buy	62,914 +48,532	+337%	+$2.66M	1.22%	24
2016 Q1	$743K	Sell	14,382 -4,920	-25%	-$256K	0.27%	65
2015 Q4	$1.35M	Hold	19,302	–	–	0.51%	47
2015 Q3	$1.2M	Sell	19,302 -55,479	-74%	-$4.37M	0.44%	55
2015 Q2	$6.29M	Sell	74,781 -10,419	-12%	-$810K	2.09%	10
2015 Q1	$6.4M	Buy	85,200 +3,132	+4%	+$219K	2.09%	9
2014 Q4	$5.1M	Buy	82,068 +7,509	+10%	+$428K	1.71%	13
2014 Q3	$3.88M	Sell	74,559 -30	-0%	-$1.53K	1.39%	21
2014 Q2	$3.83M	Sell	74,589 -19,602	-21%	-$884K	1.38%	24
2014 Q1	$4.47M	Sell	94,191 -2,124	-2%	-$109K	1.53%	17
2013 Q4	$4.18M	Buy	96,315 +83,775	+668%	+$3.47M	1.45%	21
2013 Q3	$540K	Buy	12,540 +2,340	+23%	+$94.8K	0.21%	68
2013 Q2	$354K	Buy	+10,200	New	+$358K	0.14%	83

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Hartline Investment Corp's XBI Position: Q1 2026 in Review

Hartline Investment Corp increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.7% in Q1 2026, buying an estimated $44.9K and bringing the position to 13,797 shares worth $1.76M. The position accounts for 0.19% of the portfolio, ranked #58.

Hartline Investment Corp first reported a position in XBI in Q2 2013 and has held it in 47 quarters since. The position peaked at $7.99M in Q3 2017. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Hartline Investment Corp held 13,797 shares of State Street SPDR S&P Biotech ETF worth $1.76M as of Q1 2026.
Hartline Investment Corp bought 360 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $44.9K.
State Street SPDR S&P Biotech ETF made up 0.19% of Hartline Investment Corp's portfolio in Q1 2026, its #58 holding.
Hartline Investment Corp first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 47 quarters since.
Hartline Investment Corp's State Street SPDR S&P Biotech ETF position peaked at $7.99M in Q3 2017.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Hartline Investment Corp's 13F filing for Q1 2026, filed 29 Apr 2026.